what is difference between tirzepatide and semaglutide vs Most weight loss medications work

Typical Product Appearance Typical appearance of 5-Amino-1MQ as an orange lyophilised solid

Currently, many clinical practice guidelines, including the consensus guideline of the American Diabetes Association and the European Association for the Study of Diabetes, recommend glucagon-like peptide-1 receptor agonist (GLP-1RA) as the first-line injectable agent ahead of basal insulin for most patients with T2DM ( So far, two different products containing fixed-ratio combinations (FRCs) of basal insulin and GLP-1RA were approved by the US Food and Drug Administration and European Medicines Agency: IGlarLixi, which is a combo of insulin glargine and lixisenatide, and IDegLira, which is a combo of insulin degludec and liraglutide ( Based on these backgrounds, this study aimed to evaluate the overall effect of adding basal insulin on persisting GLP-1RA treatment

PMC 1820481

Rates of super responders were highest for Zepbound (34%), followed by Wegovy (26%), Mounjaro (24%) and Ozempic (10%)